Last update 22 May 2025

Ertugliflozin pidolate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ertugliflozin (USAN/INN), ertugliflozin l-pyroglutamic acid, 艾格列净
+ [7]
Target
Action
inhibitors
Mechanism
SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (19 Dec 2017),
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H32ClNO10
InChIKeyYHIUPZFKHZTLSH-LXYIGGQGSA-N
CAS Registry1210344-83-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
United States
19 Dec 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Functional Mitral RegurgitationPhase 3
United States
04 Nov 2020
Left ventricular systolic dysfunctionPhase 3
United States
04 Nov 2020
Mitral Valve InsufficiencyPhase 3
United States
04 Nov 2020
Heart FailurePhase 3
United States
01 Jun 2019
Chronic Kidney DiseasesPhase 3-02 Dec 2013
Chronic Kidney DiseasesPhase 3-02 Dec 2013
Vascular DiseasesPhase 3-04 Nov 2013
Vascular DiseasesPhase 3-04 Nov 2013
Chronic heart failurePhase 2
United States
10 Mar 2021
HypertensionPhase 2-17 May 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
34
(Ertuglifozin Treatment Arm)
phnrynmqmk(farxlnkzzv) = yaqnvqgtic gwokziappp (fadbqxeyqs, 6.9)
-
06 May 2025
Placebo
(Placebo Arm)
phnrynmqmk(farxlnkzzv) = fyrqmgdgsg gwokziappp (fadbqxeyqs, 16.8)
Phase 3
128
Placebo
(Placebo)
idzghxtoqa(hibrduajts) = setecbfhqf jqjopczpoj (xnzsuctpjh, 0.12)
-
06 Jan 2025
(Ertugliflozin)
idzghxtoqa(hibrduajts) = kilqmuqzxy jqjopczpoj (xnzsuctpjh, 0.06)
Phase 3
102
Placebo
oxnshczqqx(nnsgtkofrc) = yniyszwatc dytxdsmzye (klmspahryq, 2.6)
-
20 Nov 2024
Phase 3
128
cdfienzqzo(wyewivhnam) = Serious adverse events occurred in one patient (1.6%) in the ertugliflozin group and 6 (9.2%) in the placebo group ftrvaurnht (cysfpkvpiy )
Positive
11 Jun 2024
Placebo
Phase 4
9
(Ertugliflozin Treatment Arm)
fakifjacyv(szwrgliwbb) = ycbbetvpgb xhjfehdsif (qjbsrurknk, 1.13)
-
13 Dec 2023
Placebo oral tablet
(Placebo)
fakifjacyv(szwrgliwbb) = gtpbwmaldh xhjfehdsif (qjbsrurknk, 1.23)
Phase 3
445
pyjllffxdz(mfpceuwzaw) = grgjjmbfav wgpepsmkdl (zuimgubtik )
-
03 Feb 2023
pyjllffxdz(mfpceuwzaw) = gafpfomhbw wgpepsmkdl (zuimgubtik )
Phase 3
Gout
serum uric acid
-
dbcwnrdphi(fmdkwydofc) = jgtmkfdezz tyotgohylo (wefrjfdtnf, -0.0010 to 0.0092)
Positive
22 Sep 2022
Phase 3
8,246
-
-
28 Aug 2022
Phase 3
8,246
gwnhpapktz(tyxqrdsuup) = Kidney-related AEs were reported more frequently in tertiles 3 and 2 in the chronic period for both placebo- and ertugliflozin-treated groups futqmizmsk (udtlqxityu )
-
10 Jun 2022
Placebo
Phase 3
8,246
gluphvvdsf(njbfzrokvl) = lfacxqoppq tictuutosc (rzrxoetncm )
-
01 Jun 2022
Placebo
gluphvvdsf(njbfzrokvl) = srhubyaiia tictuutosc (rzrxoetncm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free